MARKET

ADMS

ADMS

Adamas Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.900
-0.370
-8.67%
After Hours: 3.920 +0.02 +0.51% 17:42 10/20 EDT
OPEN
4.320
PREV CLOSE
4.270
HIGH
4.451
LOW
3.820
VOLUME
510.69K
TURNOVER
--
52 WEEK HIGH
7.45
52 WEEK LOW
1.900
MARKET CAP
110.30M
P/E (TTM)
-1.3984
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Adamas Pharma names new CMO
Adamas Pharmaceuticals ([[ADMS]] +0.8%) has appointed Adrian Quartel as Chief Medical Officer. He brings over 20 years of experience, and most recently, he was the global head of Medical Affairs at BioMarin.
Seekingalpha · 10/01 15:57
Adamas appoints new Chief Medical Officer, Adrian Quartel, MD
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Adrian Quartel, MD as Chief Medical Officer. As a member of the executive leadership
GlobeNewswire · 10/01 14:15
American Well, MediciNova among major healthcare gainers, AC Immune, Wave Life Sciences leads losers' pack
Gainers: American Well (AMWL) +17%, MediciNova (MNOV) +13%, Mallinckrodt (MNK) +7%, Capricor Therapeutics (CAPR) +8%, Adamas Pharmaceuticals (ADMS) +6%.Losers: AC Immune (ACIU) -42%, Wave Life Sciences (WVE) -34%, Rockwell Medical (RMTI) -28%, Aurora Cannabis (ACB) -23%, NanoVibronix NAOV -15%.
Seekingalpha · 09/23 14:56
Adamas presents new post-hoc data analysis for GOCOVRI® in Parkinsons disease patients with dyskinesia at the 2020 Movement Disorder Society Virtual Congress
EMERYVILLE, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI® (amantadine) extended
GlobeNewswire · 09/11 14:15
Adams Pharma Highlights Presentation Of Post-Hoc Data Analysis For GOCOVRI In Parkinson's Disease Patients With Dyskinesia At 2020 Movement Disorder Society Virtual Congress
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced today two presentations on
Benzinga · 09/11 13:17
Adamas to Present at Upcoming HC Wainwright Conference
EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive
GlobeNewswire · 09/08 20:05
Adamas Appoints Anna Richo to Board of Directors
EMERYVILLE, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Anna Richo, J.D., General Counsel
GlobeNewswire · 09/01 14:15
What Kind Of Shareholders Own Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)?
The big shareholder groups in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) have power over the company. Insiders often...
Simply Wall St. · 08/21 13:51
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADMS. Analyze the recent business situations of Adamas Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADMS stock price target is 9.31 with a high estimate of 20.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 121
Institutional Holdings: 17.69M
% Owned: 62.54%
Shares Outstanding: 28.28M
TypeInstitutionsShares
Increased
14
1.15M
New
34
-379.12K
Decreased
25
3.25M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.98%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/Lead Director/Independent Director
David Mahoney
Chief Executive Officer/Director
Neil McFarlane
Chief Financial Officer/Chief Accounting Officer
Christopher Prentiss
Other
Adrian Quartel
Other
Vijay Shreedhar
Director
John MacPhee
Director
Anna Richo
Independent Director
Michael Bigham
Independent Director
Martha Demski
Independent Director
Bill Ericson
Independent Director
Mardi Dier
Independent Director
William Ericson
Independent Director
Ivan Lieberburg
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ADMS
Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Adamas Pharmaceuticals Inc stock information, including NASDAQ:ADMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADMS stock methods without spending real money on the virtual paper trading platform.